End-of-Treatment PET/ Computed Tomography Response in Diffuse Large B-Cell Lymphoma

摘要

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease with clinicopathologic and genotypic diversity. The combination of anti-CD20 antibody, rituximab, with conventional chemotherapy that consists of cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) significantly improved survival. Nonetheless, approximately 40% of patients will relapse after first-line therapy and only a fraction of these patients will be cured.